title: Gold as an oral corticosteroid sparing agent in stable asthma.
abstract: BACKGROUND
  Patients with chronic severe asthma are often dependent on the long term prescription of oral corticosteroids. The use of steroids is associated with serious side effects. Physicians treating such patients continue to search for alternative therapies that reduce the need for chronic dosing with oral steroids. Gold compounds are immunosuppressive agents and have benefits in the treatment of a number of inflammatory disorders. They have therefore been identified as an potentially useful agents in the treatment of chronic severe asthma both in terms of possible efficacy and as steroid sparing agents.
  
  
  OBJECTIVE
  The objective of this review was to assess the effects of adding gold to oral steroids in the treatment of chronic steroid dependent asthmatics.
  
  
  METHODS
  The Cochrane Airways Group trials register and reference lists of identified articles were searched.
  
  
  METHODS
  Randomised trials looking at the addition of gold compared to placebo in adult steroid dependent asthmatics.
  
  
  METHODS
  Trial quality was assessed and data extraction was carried out by two reviewers independently. Study authors were contacted for missing information.
  
  
  RESULTS
  Three trials fulfilled the criteria for inclusion in the review and a total of 376 patients were recruited into these studies. Data from 311 patients could be analysed. There was a small but significant treatment effect for gold in terms of steroid dose reduction (Peto Odds Ratio 0.51, 95% confidence intervals 0.31,0.83). No meta-analysis could be done for measures of lung function although overall there were few changes suggesting a positive benefit for gold. There were trends suggestive of adverse effects but no significant changes for gold treated patients with respect to proteinuria (Peto Odds Ratio 1.4, 95% confidence intervals 0.6, 3.3) dermatitis/eczema Peto Odds Ratio 2.1, 95% confidence intervals 0.9, 4.7).
  
  
  CONCLUSIONS
  The changes seen in these trials are small and probably of limited clinical significance. Given the side effects of gold and necessity for monitoring the use of gold as a steroid sparing agent in asthma cannot be recommended.
authors.affiliation: Respiratory Centre, St Mary's Hospital, Milton Road, Portsmouth, UK, PO3 6AD. david.evans@smail01.porthosp.swest.nhs.uk
authors.forename: D J
authors.initials: DJ
authors.lastname: Evans
authors.forename: P
authors.initials: P
authors.lastname: Cullinan
authors.forename: D M
authors.initials: DM
authors.lastname: Geddes
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001310:Auranofin / Q000627:therapeutic use*; D006051:Aurothioglucose / Q000627:therapeutic use*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
chemical_list: D000305:Adrenal Cortex Hormones; D018927:Anti-Asthmatic Agents; D006051:Aurothioglucose; D001310:Auranofin